[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550303":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":115,"collaborators":10,"id":117,"slug":118,"hasResults":119,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":10,"eligibilityCriteria":123,"healthyVolunteers":119,"sex":124,"minAge":125,"maxAge":10,"enrollmentInfo":126,"targetDuration":10,"studyType":129,"phases":10,"briefSummary":130,"conditions":131,"keywords":136,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":158},{"fullName":5,"class":6},"Ascidian Therapeutics, Inc","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Prescreening Group",null,"The prescreening study consists of genetic and visual assessments and will require at least 1 onsite visit. All clinical assessments performed are for the purpose of determining research eligibility for ACDN-01 clinical trials.",[13],"Diagnostic Test: Prescreening Assessments",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Prescreening Assessments","Various genetic and visual assessments.",[9],[21],{"name":22,"affiliation":23,"role":24},"Alia Rashid","Ascidian Therapeutics","STUDY_DIRECTOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Associate Director, Clinical Operations","CONTACT","207-573-0412","researchtrials@ascidian-tx.com",[32,46,56,66,76,86,96,106],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":10},"University of San Francisco","RECRUITING","San Francisco","California","94158","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-122.41942,37.77493,{"lat":44,"lon":43},{"facility":47,"status":34,"city":48,"state":49,"zip":50,"country":38,"countryCode":39,"cosmosGeoPoint":51,"geoPoint":55,"contacts":10},"Vitreo Retinal Associates","Gainesville","Florida","32607",{"type":41,"coordinates":52},[53,54],-82.32483,29.65163,{"lat":54,"lon":53},{"facility":57,"status":34,"city":58,"state":59,"zip":60,"country":38,"countryCode":39,"cosmosGeoPoint":61,"geoPoint":65,"contacts":10},"Wilmer Eye Institute at John Hopkins","Baltimore","Maryland","21218",{"type":41,"coordinates":62},[63,64],-76.61219,39.29038,{"lat":64,"lon":63},{"facility":67,"status":34,"city":68,"state":69,"zip":70,"country":38,"countryCode":39,"cosmosGeoPoint":71,"geoPoint":75,"contacts":10},"Massachusetts Eye and Ear","Boston","Massachusetts","02114",{"type":41,"coordinates":72},[73,74],-71.05977,42.35843,{"lat":74,"lon":73},{"facility":77,"status":34,"city":78,"state":79,"zip":80,"country":38,"countryCode":39,"cosmosGeoPoint":81,"geoPoint":85,"contacts":10},"University of Michigan Kellogg Eye Center","Ann Arbor","Michigan","48105",{"type":41,"coordinates":82},[83,84],-83.74088,42.27756,{"lat":84,"lon":83},{"facility":87,"status":34,"city":88,"state":89,"zip":90,"country":38,"countryCode":39,"cosmosGeoPoint":91,"geoPoint":95,"contacts":10},"Cincinnati Eye Institute","Cincinnati","Ohio","45245",{"type":41,"coordinates":92},[93,94],-84.51439,39.12711,{"lat":94,"lon":93},{"facility":97,"status":34,"city":98,"state":99,"zip":100,"country":38,"countryCode":39,"cosmosGeoPoint":101,"geoPoint":105,"contacts":10},"Retina Foundation of Texas","Dallas","Texas","75382",{"type":41,"coordinates":102},[103,104],-96.80667,32.78306,{"lat":104,"lon":103},{"facility":107,"status":34,"city":108,"state":99,"zip":109,"country":38,"countryCode":39,"cosmosGeoPoint":110,"geoPoint":114,"contacts":10},"Retina Consultants of Texas","Houston","77401",{"type":41,"coordinates":111},[112,113],-95.36327,29.76328,{"lat":113,"lon":112},{"type":116,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100550303","prescreening-study-to-identify-potential-stargardt-participants-for-acdn-01-clinical-trials-starpath-100550303",false,"NCT06445322","Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)","Prescreening Study to Identify Potential Participants With ABCA4-related Retinopathy for ACDN-01 Clinical Trials","Key Inclusion Criteria:\n\n* Presence of mutations in the ABCA4 gene\n* ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy)\n\nKey Exclusion Criteria:\n\n* The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy\n* Retinal disease other than ABCA4-related retinopathy\n* Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude adherence to the scheduled study visits, safe participation in the study, or affect the results of the study.","ALL","5 Years",{"count":127,"type":128},50,"ESTIMATED","OBSERVATIONAL","This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.",[132,133,134,135],"Stargardt Disease","Stargardt Disease 1","Cone Rod Dystrophy","Juvenile Macular Degeneration",[137,138,132,139,140,141,142,143,144,145,146,147,148],"ABCA4","ABCA4-related retinopathy","Stargardt macular dystrophy","Cone rod dystrophy","Gene editing","RNA","Gene Therapy","Exon editing","IRD","Inherited retinal disease","Inherited retinal dystrophy","Inherited retinal degeneration","2026-03-09",{"date":151,"type":152},"2026-03-11","ACTUAL",{"date":154,"type":152},"2024-06-20",{"date":156,"type":128},"2030-08-31",{"name":5,"class":6},8]